High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system

Haematologica

Volumn 93, Issue 1, 2008, Pages 147-148

  Illerhaus, Gerald ^a   Müller, Fabian ^a   Feuerhake, Friedrich ^a   Schäfer, Arnd Oliver ^a   Ostertag, Christoph ^a   Finke, Jürgen ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

High dose chemotherapy; Neurotoxicity; PCNSL; Stem cell transplantation; Whole brain radiotherapy

Indexed keywords

CARMUSTINE; CYTARABINE; FOLINIC ACID; METHOTREXATE; THIOTEPA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; DRUG MEGADOSE; FOLLOW UP; HUMAN; LYMPHOMA; MINI MENTAL STATE EXAMINATION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; SEX DIFFERENCE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 38549128780     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11771     Document Type: Article

References (10)

1. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neuro-Oncol 1999;43:241-7.
2. Weller M. Glucocorticoid treatment of primary CNS lymphoma. Journal of Neuro-Oncology 1999;43:237-9.
3. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005;23:1507-13.
4. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865-70.
5. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151-6.
6. Cheng T, Forsyth P, Chaudhry A, Morris D, Gluck S, Russell JA, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003;31:679-85.
7. Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006;38:417-20.
8. Montemurro M, Kiefer T, Schuler F, Al-Ali H, Wolf HH, Herbst R, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007;18:665-71.
9. Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-43.
10. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-72.